EUVIMEDEUVIMED entdecken
Open Access

The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer

Sabeen Ikram iD, Apurv Rege, Maraki Y Negesse iD, Alexandre G Casanova iD, Nicolas Reynoird iD, Erin M Green iD

Science Advances · 17.11.2023 · 9 (46)

DOI: 10.1126/sciadv.adi5921 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 17.11.2023. Verfasst von Sabeen Ikram und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant activation of Ras/Raf/mitogen-activated protein kinase (MAPK) signaling is frequently linked to metastatic prostate cancer (PCa); therefore, the characterization of modulators of this pathway is critical for defining therapeutic vulnerabilities for metastatic PCa. The lysine methyltransferase SET and MYND domain 3 (SMYD3) methylates MAPK kinase kinase 2 (MAP3K2) in some cancers, causing enhanced activation of MAPK signaling. In PCa, SMYD3 is frequently overexpressed and associated with disease severity; however, its molecular function in promoting tumorigenesis has not been defined. We demonstrate that SMYD3 critically regulates tumor-associated phenotypes via its methyltransferase activity in PCa cells and mouse xenograft models. SMYD3-dependent methylation of MAP3K2 promotes epithelial-mesenchymal transition associated behaviors by altering the abundance of the intermediate filament vimentin. Furthermore, activation of the SMYD3-MAP3K2 signaling axis supports a positive feedback loop continually promoting high levels of SMYD3. Our data provide insight into signaling pathways involved in metastatic PCa and enhance understanding of mechanistic functions for SMYD3 to reveal potential therapeutic opportunities for PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleMiceAnimalsHumansSignal TransductionCarcinogenesisCell Transformation, NeoplasticMitogen-Activated Protein KinasesMethyltransferasesCell Line, TumorGene Expression Regulation, NeoplasticMAP Kinase Kinase Kinase 2Histone-Lysine N-Methyltransferase

Substanzen

Mitogen-Activated Protein KinasesMethyltransferasesMAP3K2 protein, humanMAP Kinase Kinase Kinase 2SMYD3 protein, humanHistone-Lysine N-Methyltransferase

Autor:innen und Institutionen

  • Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD, USA.
  • Grenoble Alpes University, CNRS UMR5309, INSERM U1209, Institute for Advanced Biosciences, Grenoble, France.
  • Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.

ORCID-Profile: Sabeen Ikram, Maraki Y Negesse, Alexandre G Casanova, Nicolas Reynoird, Erin M Green

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Ikram, S., Rege, A., Negesse, M. Y., Casanova, A. G., Reynoird, N., & Green, E. M. (2023). The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer. Science Advances, 9(46). https://doi.org/10.1126/sciadv.adi5921

Vancouver

Ikram S, Rege A, Negesse MY, Casanova AG, Reynoird N, Green EM. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer. Science Advances. 2023;9(46). doi:10.1126/sciadv.adi5921

BibTeX
@article{Ikram2023,
  author = {Ikram, Sabeen and Rege, Apurv and Negesse, Maraki Y and Casanova, Alexandre G and Reynoird, Nicolas and Green, Erin M},
  title = {The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {46},
  doi = {10.1126/sciadv.adi5921}
}
Kostenlos starten →